ReviewFrontiers in endocrinology2024
Therapeutic advances in obesity management: an overview of the therapeutic interventions.
Review in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of aerobic exercise on body composition in children and adolescents with overweight and obesity: a systematic review and meta-analysis of randomized controlled trials.BMC public health · 2025Pooled it
- An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation.International journal of obesity (2005) · 2026Trial
- Review
- Effects of Ginkgo biloba extract on glycemic control, inflammatory markers, lipid profile, anthropometric indices, and safety parameters in patients with metabolic syndrome and type 2 diabetes: a meta-analysis.Diabetology & metabolic syndrome · 2026Review
- Time-restricted feeding in rodent obesity models: impact on body weights, lipid profile and glucoregulation.International journal of obesity (2005) · 2026Review
- Pharmacological Management of Obesity in Pregnancy: A Review of Current and Emerging Therapies.Drugs · 2026Review
- Obesity treatment across healthcare levels: collaboration and digital solutions - a qualitative study of health professional and patient perspectives.BMC health services research · 2026Article
- Article
- Immunoengineering strategies using nanoparticles for obesity treatment.Nano research · 2025Article
- The safety and efficacy of extended use of an oral shape-shifting superabsorbent hydrogel capsule for weight loss: The ELECT extension study.Obesity pillars · 2025Article
- Expert consensus statement for basic research of animal exercise intervention studies in chronic disease prevention and treatment: A joint position paper of the Exercise Science branch of the Biophysical Society of China and the Metabolism and Genetics branch of the Genetics Society of China.Journal of sport and health science · 2025Article
- Transition From a High-Sugar and Butter to a Standard Diet Leads to Cecal Dysbiosis, Disrupts Intestinal Homeostasis, and Favors Increased Ethanol Consumption and Preference.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Outcomes After Hip Hemiarthroplasty for Femoral Neck Fractures in Patients With Type 2 Diabetes.Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2025Article
- Article
- The Gut Microbiome in Human Obesity: A Comprehensive Review.Biomedicines · 2025Review
- Obesity: Prevalence, causes, consequences, management, preventive strategies and future research directions.Metabolism open · 2025Review
- Prevalence and associated factors of eating disorders among metabolic bariatric surgery patients in Egypt.Journal of eating disorders · 2025Article
- Comparative Efficacy and Tolerability of Tirzepatide Versus Semaglutide at Varying Doses for Weight Loss in Non-diabetic Adults With Obesity: A Network Meta-Analysis of Randomized Controlled Trials.Cureus · 2025 · on this mapReview
- Biopsychosocial Determinants and Comorbid Risks of Obesity Among University Students: A Cross-Sectional Study.Healthcare (Basel, Switzerland) · 2025Article
- The Mechanisms of Chronic Inflammation in Obesity and Potential Therapeutic Strategies: A Narrative Review.Current issues in molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity has become a global epidemic in the modern world, significantly impacting the global healthcare economy. Lifestyle interventions remain the primary approach to managing obesity, with medical therapy considered a secondary option, often used in conjunction with lifestyle modifications. In recent years, there has been a proliferation of newer therapeutic agents, revolutionizing the treatment landscape for obesity. Notably, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, liraglutide, and the recently approved dual GLP-1/GIP RAs agonist tirzepatide, have emerged as effective medications for managing obesity, resulting in significant weight loss. These agents not only promote weight reduction but also improve metabolic parameters, including lipid profiles, glucose levels, and central adiposity. On the other hand, bariatric surgery has demonstrated superior efficacy in achieving weight reduction and addressing overall metabolic imbalances. However, with ongoing technological advancements, there is an ongoing debate regarding whether personalized medicine, targeting specific components, will shape the future of developing novel therapeutic agents for obesity management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.